111 related articles for article (PubMed ID: 660216)
1. Treatment of mouse muscular dystrophy with the protease inhibitor pepstatin.
Schorr EE; Arnason BG; Aström KE; Darzynkiewicz Z
J Neuropathol Exp Neurol; 1978 May; 37(3):263-8. PubMed ID: 660216
[TBL] [Abstract][Full Text] [Related]
2. Muscular dystrophy: inhibition of degeneration in vivo with protease inhibitors.
Stracher A; McGowan EB; Shafiq SA
Science; 1978 Apr; 200(4337):50-1. PubMed ID: 635570
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic trials in muscular dystrophy. III. Studies of microbial proteinase inhibitors in murine dystrophy.
Enomoto A; Bradley WG
Arch Neurol; 1977 Dec; 34(12):771-3. PubMed ID: 337944
[TBL] [Abstract][Full Text] [Related]
4. Delayed degeneration of dystrophic and normal muscle cell cultures treated with pepstatin, leupeptin, and antipain.
McGowan EB; Shafiq SA; Stracher A
Exp Neurol; 1976 Mar; 50(3):649-57. PubMed ID: 1253868
[No Abstract] [Full Text] [Related]
5. Treatment of experimental allergic encephalomyelitis with an inhibitor of cathepsin D (pepstatin).
Boehme DH; Umezawa H; Hashim G; Marks N
Neurochem Res; 1978 Apr; 3(2):185-94. PubMed ID: 307703
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic trial with protease inhibitor (leupeptin) in chicken muscular dystrophy. A histologic and histochemical study.
Nonaka I; Ishiura S; Takagi A; Sugita H
Acta Neuropathol; 1982; 58(4):279-85. PubMed ID: 7158305
[TBL] [Abstract][Full Text] [Related]
7. In vivo effects of protease inhibitors on chickens with hereditary muscular dystrophy.
Hudecki MS; Pollina CM; Heffner RR
J Clin Invest; 1981 Apr; 67(4):969-74. PubMed ID: 7204579
[TBL] [Abstract][Full Text] [Related]
8. The inhibition by pepstatin of cathepsin D and autolysis of dystrophic muscle.
Iodice AA
Life Sci; 1976 Nov; 19(9):1351-8. PubMed ID: 11385
[No Abstract] [Full Text] [Related]
9. Successful treatment of murine muscular dystrophy with the proteinase inhibitor leupeptin.
Sher JH; Stracher A; Shafiq SA; Hardy-Stashin J
Proc Natl Acad Sci U S A; 1981 Dec; 78(12):7742-4. PubMed ID: 6950412
[TBL] [Abstract][Full Text] [Related]
10. Pepstatin, an inhibitor of acid kininogenases and ascites retardant in neoplastic disease.
Greenbaum LM
Fed Proc; 1979 Dec; 38(13):2788-91. PubMed ID: 92421
[TBL] [Abstract][Full Text] [Related]
11. Chymostatin has no apparent beneficial effect on muscular dystrophy in the mdx mouse.
Christie KN
J Neurol Sci; 1988 Apr; 84(2-3):341-6. PubMed ID: 3379449
[TBL] [Abstract][Full Text] [Related]
12. Evidence for a defective thiol protease inhibitor in skeletal muscle of mice with hereditary muscular dystrophy.
Gopalan P; Dufresne MJ; Warner AH
Biochem Cell Biol; 1986 Oct; 64(10):1010-9. PubMed ID: 3541973
[TBL] [Abstract][Full Text] [Related]
13. Effects of stretch and denervation on protease activities of normal and dystrophic chicken muscle.
Lee YB; Ashmore CR; Hitchcock L
Exp Neurol; 1984 May; 84(2):420-7. PubMed ID: 6714351
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effect of chymostatin on dystrophic mice.
Komatsu K; Matsui A; Satoh S
Exp Neurol; 1986 Jul; 93(1):110-6. PubMed ID: 3732454
[TBL] [Abstract][Full Text] [Related]
15. Kinetics of in vivo inhibition of tissue cathepsin D by pepstatin A.
Leto G; Tumminello FM; Gebbia N; Rausa L
Int J Biochem; 1988; 20(9):917-20. PubMed ID: 3197907
[TBL] [Abstract][Full Text] [Related]
16. Gastric ulcer therapy with a pepsin-inactivating peptide, pepstatin: a double-blind randomized clinical trial.
Svendsen LB; Christiansen PM; Bonnevie O
Scand J Gastroenterol; 1979; 14(8):929-32. PubMed ID: 394302
[TBL] [Abstract][Full Text] [Related]
17. Pepstatin inhibition of rat myocardial acid protease.
Hokins BE; Smith TW
Recent Adv Stud Cardiac Struct Metab; 1976 May 26-29; 12():439-43. PubMed ID: 1031998
[TBL] [Abstract][Full Text] [Related]
18. Pepstatins: aspartic proteinase inhibitors having potential therapeutic applications.
Tumminello FM; Bernacki RJ; Gebbia N; Leto G
Med Res Rev; 1993 Mar; 13(2):199-208. PubMed ID: 8445958
[No Abstract] [Full Text] [Related]
19. Host cathepsin D response to tumor in the normal and pepstatin-treated mouse.
Greenbaum LM; Sutherland JH
Cancer Res; 1983 Jun; 43(6):2584-7. PubMed ID: 6850578
[TBL] [Abstract][Full Text] [Related]
20. Prolongation of serum half-life of interleukin 2 and augmentation of lymphokine-activated killer cell activity by pepstatin in mice.
Ohnishi H; Lin KM; Chu TM
Cancer Res; 1990 Feb; 50(4):1107-12. PubMed ID: 2297759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
